{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:11:58Z","timestamp":1793664718100,"version":"4.5.1"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2%, and Bepotastine besilate 1.5% ophthalmic solutions in the treatment of allergic conjunctivitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This is a prospective, observer-masked, comparative study of 180 patients with mild to moderate allergic conjunctivitis, randomized into three groups of 60 patients each. Each group was assigned to be treated with one of the three treatment options namely Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% ophthalmic solutions. Patients were followed-up at regular intervals with relief and resolution of symptoms and signs noted using Total Ocular Scoring System (TOSS) and hyperaemia scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      All three topical medications were effective in resolving symptoms of the patients with mild to moderate allergic conjunctivitis. Baseline mean TOSS scores for Alcaftadine group, Olopatadine group and Bepotastine besilate group were (7.68\u00b12.32), (7.65\u00b12.32) and (7.45\u00b12.27) respectively as compared to the corresponding TOSS scores on 14\n                      <jats:sup>th<\/jats:sup>\n                      Day (4\n                      <jats:sup>th<\/jats:sup>\n                      visit) which were (0.2 \u00b1 0.43), (0.4 \u00b1 0.56) and (0.1 \u00b1 0.36) respectively. The resolution of symptoms in the Bepotastine and Alcaftadine groups was significantly profound as compared to the Olopatadine group (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.008). Bepotastine and Alcaftadine groups significantly reduced allergic conjunctivitis symptoms compared to Olopatadine group (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.008).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>All three topical ophthalmic medications used in the study are safe and effective in the treatment of allergic conjunctivitis. However, Bepotastine and Alcaftadine appear to outweigh Olopatadine in resolving the symptoms of allergic conjunctivitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_2083_20","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:20:11Z","timestamp":1611015611000},"page":"257-261","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis"],"prefix":"10.4103","volume":"69","author":[{"given":"Shruti","family":"Ayyappanavar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriya","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C R","family":"Jayanthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh Babu","family":"Gangasagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B L Sujatha","family":"Rathod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Preethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20240828","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.clinthera.2012.04.024","article-title":"Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: A multicenter, randomized, investigator-masked, parallel group study in Chinese patients","volume":"34","author":"Gong","year":"2012","journal-title":"Clin Ther"},{"key":"R2-11-20240828","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2147\/OPTH.S63790","article-title":"Update and clinical utility of Alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis","volume":"9","author":"Chigbu","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"R3-11-20240828","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/JAA.S38671","article-title":"multicenter evaluation of the efficacy and duration of action of Alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model","volume":"6","author":"Ackerman","year":"2013","journal-title":"J Asthma Allergy"},{"key":"R4-11-20240828","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1755-3768.2008.01265.x","article-title":"Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: A placebo-controlled environmental trial","volume":"87","author":"Borazan","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"R5-11-20240828","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s12325-014-0155-3","article-title":"Ocular itch relief with Alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: Pooled analysis of two multicentre randomized clinical trials","volume":"31","author":"McLaurin","year":"2014","journal-title":"Adv Ther"},{"key":"R6-11-20240828","first-page":"9","article-title":"Alcaftadine, a new antihistamine with combined antagonistic activity at histamine H1, H2 and H4 receptors","volume":"5","author":"Gallois-Bernos","year":"2012","journal-title":"J Receptor Ligand Channel Res"},{"key":"R7-11-20240828","first-page":"53","article-title":"Alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis","volume":"7","author":"Meena","year":"2018","journal-title":"Int J Sci Res"},{"key":"R8-11-20240828","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2147\/OPTH.S35431","article-title":"Comparative efficacy of Bepotastine besilate 1.5% ophthalmic solution versus Olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference","volume":"6","author":"McCabe","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"R9-11-20240828","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.4103\/ijo.IJO_2112_18","article-title":"Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and Alcaftadine (0.25%) in mild to moderate allergic conjunctivitis","volume":"67","author":"Dudeja","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"R10-11-20240828","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/187221311794474883","article-title":"Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis","volume":"5","author":"Mishra","year":"2011","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"R11-11-20240828","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/BF02854842","article-title":"Efficacy and safety of ketorolac tromethamine 0.5% andlevocabastine 0.05%: A multicentre comparison in patients with seasonalallergic conjunctivitis","volume":"17","author":"Donshik","year":"2000","journal-title":"Adv Ther"},{"key":"R12-11-20240828","first-page":"77","article-title":"Comparison of effects of Alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis","volume":"5","author":"Ono","year":"2011","journal-title":"Drug Des Devel Ther"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2083_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:37:45Z","timestamp":1787845065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2083_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2083_20","relation":{},"ISSN":["0301-4738"],"issn-type":[{"value":"0301-4738","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}